Ernexa Therapeutics Inc. Interest Paid, Including Capitalized Interest, Operating and Investing Activities
Ernexa Therapeutics Inc. (ERNA) reported Interest Paid, Including Capitalized Interest, Operating and Investing Activities of $303.00 thousand for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-04.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:InterestPaid · last filed 2017-08-04
- Ernexa Therapeutics Inc. interest paid, including capitalized interest, operating and investing activities for the quarter ending 2017-06-30 was $132.00K, a 0.75% decline year-over-year.
- Ernexa Therapeutics Inc. interest paid, including capitalized interest, operating and investing activities for the quarter ending 2017-03-31 was $171.00K, a 103.57% increase year-over-year.
- Ernexa Therapeutics Inc. interest paid, including capitalized interest, operating and investing activities for the quarter ending 2016-12-31 was $135.00K, a 610.53% increase year-over-year.
- Ernexa Therapeutics Inc. interest paid, including capitalized interest, operating and investing activities for the quarter ending 2016-09-30 was $140.00K, a 115.38% increase year-over-year.
- Ernexa Therapeutics Inc. interest paid, including capitalized interest, operating and investing activities for fiscal 2016 was $492.00K, a 49.09% increase from fiscal 2015.
- Ernexa Therapeutics Inc. interest paid, including capitalized interest, operating and investing activities for fiscal 2015 was $330.00K, a 48.65% increase from fiscal 2014.
- Ernexa Therapeutics Inc. interest paid, including capitalized interest, operating and investing activities for fiscal 2014 was $222.00K.
| Period end | Interest Paid, Including Capitalized Interest, Operating and Investing Activities 3 month | Interest Paid, Including Capitalized Interest, Operating and Investing Activities 6 month | Interest Paid, Including Capitalized Interest, Operating and Investing Activities 9 month | Interest Paid, Including Capitalized Interest, Operating and Investing Activities 12 month |
|---|---|---|---|---|
| 2017-06-30 | $132.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $303.00K 10-Q · filed 2017-08-04 | $438.00K derived: sum of 3 quarters · filed 2017-08-04 | $578.00K derived: sum of 4 quarters · filed 2017-08-04 |
| 2017-03-31 | $171.00K 10-Q · filed 2017-05-04 | $306.00K derived: sum of 2 quarters · filed 2017-05-04 | $446.00K derived: sum of 3 quarters · filed 2017-05-04 | $579.00K derived: sum of 4 quarters · filed 2017-08-04 |
| 2016-12-31 | $135.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $275.00K derived: sum of 2 quarters · filed 2017-03-09 | $408.00K derived: sum of 3 quarters · filed 2017-08-04 | $492.00K 10-K · filed 2017-03-09 |
| 2016-09-30 | $140.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $273.00K derived: sum of 2 quarters · filed 2017-08-04 | $357.00K 10-Q · filed 2016-11-09 | $376.00K derived: sum of 4 quarters · filed 2017-08-04 |
| 2016-06-30 | $133.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $217.00K 10-Q · filed 2017-08-04 | $236.00K derived: sum of 3 quarters · filed 2017-08-04 | $301.00K derived: sum of 4 quarters · filed 2017-08-04 |
| 2016-03-31 | $84.00K 10-Q · filed 2017-05-04 | $103.00K derived: sum of 2 quarters · filed 2017-05-04 | $168.00K derived: sum of 3 quarters · filed 2017-05-04 | $311.00K derived: sum of 4 quarters · filed 2017-05-04 |
| 2015-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $84.00K derived: sum of 2 quarters · filed 2017-03-09 | $227.00K derived: sum of 3 quarters · filed 2017-03-09 | $330.00K 10-K · filed 2017-03-09 |
| 2015-09-30 | $65.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $208.00K derived: sum of 2 quarters · filed 2016-11-09 | $311.00K 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $143.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $246.00K 10-Q · filed 2016-08-04 | ||
| 2015-03-31 | $103.00K 10-Q · filed 2016-05-09 | |||
| 2014-12-31 | $222.00K 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |